Database→PE 22-28

Tier 4CognitiveNeuroprotectionMood / AntidepressantPREMIUM

PE 22-28

PE 22-28 (Mini-Spadin) -- Sortilin Propeptide Fragment, TREK-1 Potassium Channel Antagonist

Research compound only. No FDA approval, no IND filed, no ClinicalTrials.gov registration for any indication. No clinical trials have administered PE 22-28 to human subjects as of March 2026. Not on WADA Prohibited List.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

PE 22-28 is a synthetic 7-amino acid peptide derived from positions 22 to 28 of the sortilin propeptide (PE). It is the most potent known selective TREK-1 potassium channel antagonist, with an IC50 of 0.12 nM versus 40 to 60 nM for its parent compound spadin, and produces antidepressant-like effects within 4 days in mouse behavioral models versus 21 days for fluoxetine. All evidence is preclinical from a single French research group. No human has received PE 22-28 in a clinical trial.

🔒

Full Profile: Premium Members Only

The complete PE 22-28 profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use